Tumor Necrosis Factor Receptor Superfamily, Member 17 (TNFRSF17) ELISA Kits

The protein encoded by TNFRSF17 is a member of the TNF-receptor superfamily. Zusätzlich bieten wir Ihnen TNFRSF17 Antikörper (110) und TNFRSF17 Proteine (65) und viele weitere Produktgruppen zu diesem Protein an.

list all ELISA KIts Gen GeneID UniProt
Anti-Ratte TNFRSF17 TNFRSF17 287034  
TNFRSF17 608 Q02223
TNFRSF17 21935 O88472
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen
  • orders@antikoerper-online.de

Top TNFRSF17 ELISA Kits auf antikoerper-online.de

Showing 5 out of 13 products:

Katalog Nr. Reaktivität Sensitivität Bereich Bilder Menge Lieferzeit Preis Details
Human 10pg/mL 31.2-2000 pg/mL Human TNFRSF17/BCMA PicoKine ELISA Kit standard curve 96 Tests 4 bis 6 Tage
$369.00
Details
Maus 10pg/mL 31.2-2000 pg/mL Mouse TNFRSF17/BCMA PicoKine ELISA Kit standard curve 96 Tests 4 bis 6 Tage
$369.00
Details
Human 4.8 pg/mL n/a   96 Tests 11 bis 16 Tage
$673.75
Details
Maus
  96 Tests 26 bis 36 Tage
$899.80
Details
Maus < 0.101 ng/mL 0.312 ng/mL - 20 ng/mL   96 Tests 11 bis 18 Tage
$902.56
Details

Weitere ELISA Kits für TNFRSF17 Interaktionspartner

Human Tumor Necrosis Factor Receptor Superfamily, Member 17 (TNFRSF17) Interaktionspartner

  1. these data support the further development of anti-BCMA CAR T cells as a potential treatment for not only multiple myeloma (MM)but also some lymphomas

  2. Expression patterns of BAFF and its receptor BCMA differ according to lupus nephritis class.

  3. High BCMA expression is associated with primary central nervous system lymphoma.

  4. soluble BCMA sequesters circulating BAFF, thereby preventing it from performing its signaling to stimulate normal B-cell and plasma cell development, resulting in reduced polyclonal antibody levels in multiple myeloma patients.

  5. Studied expression of B-cell maturation antigen (BCMA) in osteoblasts and the toxic effect of chromium on its expression; found BCMA is involved in osteogenesis of osteoblasts; chromium downregulates expression of BCMA in osteoblasts.

  6. BCMA has other contributors for ligands binding except DxL motif. The affinity of BCMA for APRIL higher than for BAFF may be caused by the segment outside of the conservative DxL motif. Moreover, the exposition of new binding modes of BCMA2 interacting with APRIL may establish the foundation of designing novel drugs in the future

  7. New molecular mechanisms of in vivo Multiple Myeloma (MM) growth and immunosuppression critically dependent on BCMA and APRIL in the Bone marrow microenvironment, further supporting targeting this prominent pathway in MM.

  8. We have identified a specific serum protein, BCMA, as a novel independent marker for both monitoring and predicting outcomes for MM patients. We have shown that sBCMA is elevated in MM patients, and can be used to follow their disease status, PFS and OS.

  9. The expression levels of serum BAFF and the three receptors (TACI, BCMA and BAFF-R) in non-Hodgkin lymphoma patients were significantly higher than in healthy controls.

  10. Decreased BCMA expression on peripheral B cells according to severe disease activity suggests that BCMA plays an important regulating role in B-cell hyperactivity and immune tolerance homeostasis in systemic lupus erythematosus patients

  11. results suggest that Akt and JNK pathways are involved in the regulation of B-cell maturation antigen (BCMA)

  12. shedding of BCMA by gamma-secretase controls plasma cells in the bone marrow and yields a potential biomarker for B-cell involvement in human autoimmune diseases

  13. elevated serum levels in patients with Behcet's disease

  14. Data show significant differences in expression of tumour necrosis factor family (BAFF) receptors BAFF-R, BCMA and TACI in patients with and without anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies.

  15. High BCMA expression is associated with breast cancer.

  16. BAFF and APRIL as well as their cognate receptors (BCMA, TACI) correlate with glioma grade. (Meta-analysis)

  17. The B cell maturation antigen (BCMA) is a tumor necrosis family receptor member that is predominantly expressed on terminally differentiated B cells and, upon binding to its ligands B cell activator of the TNF family and a proliferation inducing ligand.

  18. Activation of B cells through BCMA regulates spinal cord injury-induced autoimmunity via a proliferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF).

  19. Data indicate that MAGE3, Survivin and B-cell maturation antigen (BCMA) mRNA-pulsed dendritic cells (DCs) are capable of stimulating tumor-associated antigens (TAA)-specific T-cell responses in multiple myeloma (MM) patients.

  20. Data indicate that B-cell maturation antigen (BCMA) is a suitable target for chimeric antigen receptor (CAR)-expressing T cells, and adoptive transfer of anti-BCMA-CAR-expressing T cells is a promising new strategy for treating multiple myeloma.

Mouse (Murine) Tumor Necrosis Factor Receptor Superfamily, Member 17 (TNFRSF17) Interaktionspartner

  1. high affinity antibody blocks the binding of the native ligands APRIL and BAFF to BCMA. This finding is rationalized by the high resolution crystal structure of the Fab fragment in complex with the extracellular domain of BCMA

  2. Elimination of B lymphocyte stimulator receptor 3 (BR-3) and BCMA inhibits the development of SLE in NZM mice.

  3. we have identified a novel role for BCMA to control excess BAFF production in murine lupus through restraining the accumulation of BAFF-producing neutrophils.

  4. Heteromers consisting of one BAFF and two APRIL bind to receptor TACI, BCMA but not to BAFFR.

  5. BCMA is dispensable for the development of SLE in NZM mice. BAFF-BCMA interactions contribute to SLE.

  6. Study reveals that BCMA works to control B cell homeostasis and self-tolerance in systemic autoimmunity.

  7. Blimp-1 is a positive regulator of the expression of BCMA gene in mouse plasma cells.

  8. The 5'-flanking sequence from -820 to +145 bp of BCMA is of promoter activity.

  9. A vital role of BCMA in bone marrow plasma cell survival.

  10. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells.

  11. Review. APRIL interactions with BCMA likely govern memory B cell populations.

  12. Review. Direct BAFF/APRIL signalling in T cells and/or T cell modulation in response to a BAFF-modified B cell compartment may play an important role in inflammation and immunomodulation.

TNFRSF17 Antigen-Profil

Beschreibung des Gens

The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation.

Genbezeichner und Symbole assoziert mit TNFRSF17

  • TNF receptor superfamily member 17 (Tnfrsf17) Antikörper
  • TNF receptor superfamily member 17 (TNFRSF17) Antikörper
  • tumor necrosis factor receptor superfamily, member 17 (Tnfrsf17) Antikörper
  • BCM Antikörper
  • BCMA Antikörper
  • CD269 Antikörper
  • Tnfrsf13 Antikörper
  • Tnfrsf13a Antikörper
  • TNFRSF17 Antikörper

Bezeichner auf Proteinebene für TNFRSF17

tumor necrosis factor receptor superfamily member 17 , tumor necrosis factor receptor superfamily, member 17 , B cell maturation antigen , B-cell maturation factor , B-cell maturation protein

GENE ID SPEZIES
287034 Rattus norvegicus
467905 Pan troglodytes
712212 Macaca mulatta
608 Homo sapiens
21935 Mus musculus
Ausgewählte Anbieter für TNFRSF17 (TNFRSF17) ELISA Kits
Haben Sie etwas anderes gesucht?